{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:25:07Z","timestamp":1792682707309,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["155851"],"award-info":[{"award-number":["155851"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["174281"],"award-info":[{"award-number":["174281"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI069924"],"award-info":[{"award-number":["U01AI069924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jclinepi.2022.02.005","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T18:15:40Z","timestamp":1645294540000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7221-1929","authenticated-orcid":false,"given":"Anthony","family":"Hauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fardo","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina L.","family":"Reichmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Kouyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2022.02.005_bib0001","unstructured":"UNAIDS. Ending the AIDS epidemic by 2030."},{"issue":"9","key":"10.1016\/j.jclinepi.2022.02.005_bib0002","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/AAC.44.9.2475-2484.2000","article-title":"Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy","volume":"44","author":"Bacheler","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jclinepi.2022.02.005_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007083","article-title":"Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa","volume":"15","author":"Hauser","year":"2019","journal-title":"PLOS Comput Biol"},{"issue":"1","key":"10.1016\/j.jclinepi.2022.02.005_bib0004","first-page":"1","article-title":"Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study","volume":"21","author":"Riou","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0005","unstructured":"World Health Organization (WHO). HIV drug resistance report 2017 [Internet]. 2017 [cited 2020 Nov 19]. Available from:https:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-report-2017\/en\/."},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0006","series-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection [Internet]. WHO","year":"2016"},{"issue":"1","key":"10.1016\/j.jclinepi.2022.02.005_bib0007","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/jac\/dkw358","article-title":"HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa","volume":"72","author":"Steegen","year":"2017","journal-title":"J Antimicrob Chemother [Internet]"},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0008","article-title":"HIV-1 antiretroviral resistance: Scientific principles and clinical applications [Internet]","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs. Drugs"},{"issue":"Suppl 3","key":"10.1016\/j.jclinepi.2022.02.005_bib0009","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/00002030-200406003-00012","article-title":"HIV-1 subtype distribution and the problem of drug resistance","author":"Wainberg","year":"2004","journal-title":"AIDS"},{"issue":"19","key":"10.1016\/j.jclinepi.2022.02.005_bib0010","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1128\/JVI.00872-07","article-title":"Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications","volume":"81","author":"Buonaguro","year":"2007","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.jclinepi.2022.02.005_bib0011","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/JVI.01349-08","article-title":"Template usage is responsible for the preferential acquisition of the k65r reverse transcriptase mutation in subtype c variants of human immunodeficiency virus type 1","volume":"83","author":"Coutsinos","year":"2009","journal-title":"J Virol [Internet]"},{"issue":"8","key":"10.1016\/j.jclinepi.2022.02.005_bib0012","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1086\/605894","article-title":"Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the k65r resistance mutation in HIV-1 Subtype C","volume":"200","author":"Invernizzi","year":"2009","journal-title":"J Infect Dis [Internet]"},{"issue":"9","key":"10.1016\/j.jclinepi.2022.02.005_bib0013","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/infdis\/jiw213","article-title":"No evidence that HIV-1 subtype c infection compromises the efficacy of tenofovir-containing regimens: cohort study in the United Kingdom","volume":"214","author":"White","year":"2016","journal-title":"J Infect Dis [Internet]"},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0014","unstructured":"UNAIDS. AIDSinfo. Number of people living with HIV [Internet]. [cited 2018]. Available from:http:\/\/aidsinfo.unaids.org\/."},{"issue":"1","key":"10.1016\/j.jclinepi.2022.02.005_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev."},{"issue":"s1","key":"10.1016\/j.jclinepi.2022.02.005_bib0016","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J Infect Dis [Internet]"},{"issue":"D1","key":"10.1016\/j.jclinepi.2022.02.005_bib0017","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1093\/nar\/gkaa1023","article-title":"GenBank","volume":"49","author":"Sayers","year":"2021","journal-title":"Nucleic Acids Res [Internet]"},{"issue":"10","key":"10.1016\/j.jclinepi.2022.02.005_bib0018","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/e19100555","article-title":"The prior can often only be understood in the context of the likelihood","volume":"19","author":"Gelman","year":"2017","journal-title":"Entropy [Internet]."},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0019","first-page":"1679","article-title":"Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa","volume":"24","author":"El-Khatib","year":"2010","journal-title":"Wolters Kluwer Heal | Lippincott Williams Wilkins AIDS Wolters Kluwer Heal [Internet]"},{"issue":"9","key":"10.1016\/j.jclinepi.2022.02.005_bib0020","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1093\/jac\/dkv143","article-title":"Determinants of virological failure and antiretroviral drug resistance in Mozambique","volume":"70","author":"Rup\u00e9rez","year":"2015","journal-title":"J Antimicrob Chemother [Internet]"},{"issue":"4","key":"10.1016\/j.jclinepi.2022.02.005_bib0021","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/QAI.0b013e3181bc478b","article-title":"Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa","volume":"53","author":"Wallis","year":"2010","journal-title":"JAIDS J Acquir Immune Defic Syndr [Internet]"},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0022","doi-asserted-by":"crossref","unstructured":"Williams DR, Rast P, B\u00fcrkner P-C. Bayesian meta-analysis with weakly informative prior distributions. 2018 [cited 2021 Dec 4]; Available from:https:\/\/psyarxiv.com\/7tbrm\/.","DOI":"10.31234\/osf.io\/7tbrm"},{"issue":"10","key":"10.1016\/j.jclinepi.2022.02.005_bib0023","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1086\/587109","article-title":"Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in kwazulu natal, South Africa","volume":"46","author":"Marconi","year":"2008","journal-title":"Clin Infect Dis [Internet]."},{"issue":"7","key":"10.1016\/j.jclinepi.2022.02.005_bib0024","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1089\/aid.2006.0298","article-title":"The reverse transcriptase 67N 70R 215Y genotype is the predominant tam pathway associated with virologic failure among hiv type 1c-infected adults treated with ZDV\/ddI-Containing HAART in Southern Africa","volume":"23","author":"Novitsky","year":"2007","journal-title":"AIDS Res Hum Retroviruses [Internet]"},{"issue":"2","key":"10.1016\/j.jclinepi.2022.02.005_bib0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/hiv.12400","article-title":"HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa","volume":"18","author":"Rossouw","year":"2017","journal-title":"HIV Med [Internet]"},{"issue":"7","key":"10.1016\/j.jclinepi.2022.02.005_bib0026","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/jmv.24162","article-title":"Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia","volume":"87","author":"Seu","year":"2015","journal-title":"J Med Virol [Internet]"},{"issue":"3","key":"10.1016\/j.jclinepi.2022.02.005_bib0027","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/QAI.0b013e318228667f","article-title":"Drug resistance and viral tropism in HIV-1 subtype C-infected patients in kwazulu-natal, South Africa","volume":"58","author":"Singh","year":"2011","journal-title":"JAIDS J Acquir Immune Defic Syndr [Internet]"},{"issue":"13","key":"10.1016\/j.jclinepi.2022.02.005_bib0028","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","article-title":"High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen","volume":"26","author":"Sunpath","year":"2012","journal-title":"AIDS [Internet]"},{"issue":"2","key":"10.1016\/j.jclinepi.2022.02.005_bib0029","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3851\/IMP2010","article-title":"Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients","volume":"17","author":"Barth","year":"2012","journal-title":"Antivir Ther [Internet]"},{"issue":"5","key":"10.1016\/j.jclinepi.2022.02.005_bib0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/cid\/cis501","article-title":"Frequent emergence of N348I in HIV-1 subtype c reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors","volume":"55","author":"Brehm","year":"2012","journal-title":"Clin Infect Dis [Internet]"},{"issue":"12","key":"10.1016\/j.jclinepi.2022.02.005_bib0031","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1086\/648444","article-title":"Viremia, resuppression, and time to resistance in Human Immunodeficiency Virus (HIV) Subtype C during first-line antiretroviral therapy in South Africa","volume":"49","author":"Hoffmann","year":"2009","journal-title":"Clin Infect Dis [Internet]"},{"issue":"7","key":"10.1016\/j.jclinepi.2022.02.005_bib0032","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP2652","article-title":"Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa","volume":"18","author":"Hoffmann","year":"2013","journal-title":"Antivir Ther [Internet]"},{"issue":"11","key":"10.1016\/j.jclinepi.2022.02.005_bib0033","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1093\/jac\/dkx252","article-title":"Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa","volume":"72","author":"Hunt","year":"2017","journal-title":"J Antimicrob Chemother [Internet]"},{"issue":"28","key":"10.1016\/j.jclinepi.2022.02.005_bib0034","doi-asserted-by":"crossref","first-page":"e3985","DOI":"10.1097\/MD.0000000000003985","article-title":"Should viral load thresholds be lowered?","volume":"95","author":"Labhardt","year":"2016","journal-title":"Medicine (Baltimore) [Internet]"},{"issue":"9","key":"10.1016\/j.jclinepi.2022.02.005_bib0035","article-title":"Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania","volume":"15","author":"Mziray","year":"2020","journal-title":"PLoS One [Internet]"},{"issue":"5","key":"10.1016\/j.jclinepi.2022.02.005_bib0036","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"Gregson","year":"2016","journal-title":"Lancet Infect Dis [Internet]."},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0037","article-title":"2019 ART clinical guidelines for the management of HIV in adults, pregnancy, adolescents, children","year":"2020","journal-title":"Infants and Neonates"},{"issue":"4","key":"10.1016\/j.jclinepi.2022.02.005_bib0038","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0039","series-title":"Conference on Retroviruses and Opportunistic Infections [Internet].","article-title":"DTG VS. LPV\/R IN SECOND LINE (DAWNING): OUTCOMES BY WHO-RECOMMENDED NRTI BACKBONE | CROI Conference","author":"Aboud","year":"2018"},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0040","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.1","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis","volume":"7","author":"Wandeler","year":"2018","journal-title":"F1000Research"},{"issue":"1","key":"10.1016\/j.jclinepi.2022.02.005_bib0041","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1473-3099(17)30630-8","article-title":"Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial","volume":"18","author":"Hakim","year":"2018","journal-title":"Lancet Infect Dis [Internet]."},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0042","article-title":"Effectiveness of protease inhibitor\/nucleos(t)ide reverse transcriptase inhibitor\u2013based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-saharan Africa: a systematic review and meta-analysis","author":"Stockdale","year":"2017","journal-title":"Clin Infect Dis [Internet]"},{"issue":"2","key":"10.1016\/j.jclinepi.2022.02.005_bib0043","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","article-title":"Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis","volume":"2","author":"Boyd","year":"2015","journal-title":"Lancet HIV [Internet]"},{"issue":"8","key":"10.1016\/j.jclinepi.2022.02.005_bib0044","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/AAC.48.8.3122-3126.2004","article-title":"Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing","volume":"48","author":"Rhee","year":"2004","journal-title":"Antimicrob Agents Chemother [Internet]"},{"issue":"1","key":"10.1016\/j.jclinepi.2022.02.005_bib0045","article-title":"A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","volume":"17","author":"Brenner","year":"2003","journal-title":"AIDS [Internet]"},{"issue":"1","key":"10.1016\/j.jclinepi.2022.02.005_bib0046","first-page":"3","article-title":"Update on HIV-1 acquired and transmitted drug resistance in Africa","volume":"17","author":"Ssemwanga","year":"2015","journal-title":"AIDS Rev [Internet]"},{"issue":"3","key":"10.1016\/j.jclinepi.2022.02.005_bib0047","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","article-title":"Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review","volume":"10","author":"Barth","year":"2010","journal-title":"Lancet Infect Dis [Internet]"},{"issue":"9","key":"10.1016\/j.jclinepi.2022.02.005_bib0048","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/civ556","article-title":"Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis","volume":"61","author":"Boender","year":"2015","journal-title":"Clin Infect Dis [Internet]"},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0049","series-title":"HIV Drug Resistance Report 2017 [Internet]","year":"2017"},{"key":"10.1016\/j.jclinepi.2022.02.005_bib0050","first-page":"409","volume":"9","author":"Gupta","year":"2009"},{"issue":"7","key":"10.1016\/j.jclinepi.2022.02.005_bib0051","article-title":"Trends in CD4 and viral load testing 2005 to 2018: multi-cohort study of people living with HIV in Southern Africa","volume":"23","author":"Zaniewski","year":"2020","journal-title":"J Int AIDS Soc [Internet]."}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435622000439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435622000439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:24:45Z","timestamp":1760246685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435622000439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":51,"alternative-id":["S0895435622000439"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2022.02.005","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2022.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}